Reuters logo
BRIEF-Genmab announces positive topline results in Phase III ALCYONE study of daratumumab in front line multiple myeloma
August 24, 2017 / 1:34 PM / 3 months ago

BRIEF-Genmab announces positive topline results in Phase III ALCYONE study of daratumumab in front line multiple myeloma

Aug 24 (Reuters) - GENMAB:

* GENMAB ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE III ALCYONE STUDY OF DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

* SAYS ‍TREATMENT WITH DARATUMUMAB REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 50%, AS COMPARED TO THOSE WHO DID NOT RECEIVE DARATUMUMAB​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below